Fig. 2: In vitro cell growth inhibition by ADC and internalisation of GPC-1 ADC.
From: Anti-glypican-1 antibody–drug conjugate is a potential therapy against pancreatic cancer
a Flow cytometry of GPC-1 expression in BxPC-3, T3M-4 and SUIT-2 using anti-GPC-1 monoclonal antibody. b BxPC-3, T3M-4 and SUIT-2 cells were treated with anti-GPC-1 monoclonal antibody (clone 01a033) or control IgG antibody for 144 h. Neither antibody inhibited the growth of any cell line. c Cells were treated with GPC-1-ADC or mouse IgG2a-ADC (a control ADC) for 144 h. Relative to control ADC, GPC-1-ADC significantly inhibited the growth of GPC-1-positive BxPC-3 and T3M-4 cell lines. Neither treatment inhibited the growth of the GPC-1-negative SUIT-2 cell line. d Time course of the internalisation activity of GPC-1-ADC in BxPC-3 and T3M-4 cells. e GPC-1-ADC internalises and locates in the lysosomes of BxPC-3 cells. Plasma membrane and intracellular GPC-1 were visualised by confocal fluorescence microscopy. Green indicates GPC-1-ADC, red indicates the lysosomal marker LAMP-1 and blue indicates DAPI (4′,6-diamidino-2-phenylindole)-stained DNA. Scale bar: 10 μm. GPC-1-ADC was found in the lysosomes. GPC-1-ADC and the lysosomal marker LAMP-1 overlapped (arrow).
